Courtney Scott, MD
Addiction Medicine · Inglewood, CANPI 1699906750
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Alkermes, Inc. at 54.3% of the total.
Across 28 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$293
- Indivior Inc.$69
- Gilead$66
- Kowa Pharmaceuticals America, Inc.$35
- GSK$31
- Novo Nordisk$24
- plus $22 from 1 others
What the payments were for
- Food & beverage$51295%
- Education$285%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 15 | $293 |
| Indivior Inc. | 4 | $69 |
| Gilead | 3 | $66 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| GSK | 2 | $31 |
| Novo Nordisk | 1 | $24 |
| Masimo Corporation | 1 | $22 |
How this compares
$540 in reported general payments places this provider in the 65th percentile of 190 addiction medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 19 | $92,964 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 37 | $50,940 |
| Ketoprofen | 18 | $37,728 |
| Diflorasone Diacetate | 24 | $29,141 |
| Naproxen | 49 | $26,573 |
| Famotidine | 44 | $23,020 |
| CrotanCrotamiton | 15 | $18,478 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $2,458 |
| Oxycodone Hcl | 11 | $115 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Inglewood
- Tipu KhanVentura$262K
- Anthony AlbaneseMather$135K
- Matthew TorringtonCulver City$77K
- Kenneth StarrArroyo Grande$64K
- Drew PinskySouth Pasadena$60K
- Mark HonzelBeverly Hills$27K
- Bryan HylerVista$17K
- Abraham MalkinLos Angeles$12K
- Jonathan ReitmanBeverly Hills$11K
- Caleb LuskSan Pedro$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.